Tech

Bio-Techneの空売り状況は、投資家がBio-Techneの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Bio-Techne (NASDAQ:TECH) 株価情報, 空売り情報

BIO-TECHNE CORP

Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Corp

TECHLEAD NPN PCL by TECHLEAD NPN PUB CO LTD.

TECHNISCAN INC by TechniScan, Inc.

TECHNOLOGY & TELECOMMUNICATION ACQUISITION CORP UNIT 1 CL A SHS & 1WT EXP

TECHNOLOGY & TELECOMMUNICATION ACQUISITION CORP WT EXP

TECHNOLOGY MTLS AUSTRALIA by TECHNOLOGY METALS AUSTRALIA LTD

TECHNOPROBE SPA U/ADR by TECHNOPROBE SPA

TECHWING INC by Techwing, Inc.

Tech Central Inc

TechTarget Inc

Techcom Inc

Techmatrix Corp

TECHNICAL COMMUNICATIONS by Technical Communications Corp.

Technical Communications Corp

TECHNIP ENERGIES S/ADR by Technip Energies NV

Technip Energies NV

TECHNIP ENERGIES NV by Technip Energies NV

TechnipFMC PLC

TECHNO HORIZON CO LTD by Techno Horizon Co Ltd.

Techno Horizon Co Ltd

TECHNOPRO HLDGS SP/ADR by Technopro Holdings Inc.

TechnoPro Holdings Inc

TECHNOPRO HLDGS INC ORD by Technopro Holdings Inc.

Technogym SpA

Technology & Telecommunication Acquisition Corp Warrants (13/01/2027)

Technology & Telecommunication Acquisition Corp

Technology & Telecommunication Acquisition Corp Units (1 Ord Class A & 1 War)

TECHNOLOGY&TELECOMM A by Technology & Telecommunication Acquisition Corporation

TECHNOLOGY GENERAL CORP by Technology General Corp.

Technology General Corp

TECHNOLOGY ONE LTD by Technology One, Ltd.

Technology One Ltd

TECHNOLOGY SLTNS CO by Technology Solutions Company

Technology Solutions Co

TECHNOVATIVE GRP INC by Technovative Group, Inc.

Technovative Group Inc

Techpoint Inc

Techprecision Corp

TECHTRONIC INDUS CO ORD by Techtronic Industries Ltd.

Techtronic Industries Co Ltd

TECHTRONIC INDUS LTD ADR by Techtronic Industries Ltd.

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

News

Price Target

Analyst Ratings

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

RBC Capital analyst Conor McNamara maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Sector Perform and lowers the price target from $72 to $63.

RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $63

Benchmark analyst Robert Wasserman maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $75.

Benchmark Maintains Buy on Bio-Techne, Lowers Price Target to $75

Stifel analyst Daniel Arias maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Hold and lowers the price target from $75 to $60.

Stifel Maintains Hold on Bio-Techne, Lowers Price Target to $60

<ul>
<li>Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.</li>
<li>The TcBuster&#x2122; system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect&#xAE; continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.</li>
<li>The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a non-viral gene-editing workflow ideal for the development of advanced cell therapies.</li>
<li>The data will be presented in a poster at ISCT, May 7-10, 2025, in New Orleans.</li>
</ul>
CAMBRIDGE, Mass. and MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster&#x2122; GMP non-viral genome engineering system and the Flowfect Tx&#x2122; GMP cellular engineering platform. Together, these technologies offer a clear path to shortened workflows for generating more efficient genome engineering of immune cell therapies, expediting their advancement to clinical stages and subsequent manufacturing.

Kytopen And Bio-Techne Partner To Streamline Gene Delivery Solutions For Development And Manufacture Of Advanced Cell Therapies

WIIM

TECH stock has given up its prior gain. Bio-Techne shares were trading higher after the company reported better-than-expected Q3 adjusted EPS results. Also, the company approved a $500 million buyback.

Bio-Techne shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results. Also, the company approved a $500 million buyback.

Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended, or discontinued at any time and does not obligate the Company to acquire any specific dollar amount or number of shares of common stock.

Buybacks

Bio-Techne Board Approves New Stock Buyback Of $500M

Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.51 by 9.8 percent. This is a 16.67 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $316.18 million which missed the analyst consensus estimate of $317.53 million by 0.43 percent. This is a 4.20 percent increase over sales of $303.43 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Bio-Techne Q3 Adj. EPS $0.56 Beats $0.51 Estimate, Sales $316.18M Miss $317.53M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

<a href="https://www.quiverquant.com/congresstrading/politician/April%20McClain%20Delaney-M001232" title="https://www.quiverquant.com/congresstrading/politician/April%20McClain%20Delaney-M001232">https://www.quiverquant.com/congresstrading/politician/April%20McClain%20Delaney-M001232</a>

Politics

Trading Ideas

General

Watching Bio-Techne; Shares See A Pop In Volume, Traders Circulate Quiver Quantitative Update Showing Representative April McClain Delaney Filed A New Position Between $1,001-$15,000 In The Company

A report on May 2, 2025 shows that Representative April McClain Delaney from Maryland purchase stock in Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), valued between $13,013 and $195,000. According to the May filing, the transaction occurred on May 2, 2025.
At the time of writing, Bio-Techne shares are trading up 0.41% at $50.7.
<h3>Representative's Recent Trading Activity</h3>
In the past three years, April McClain Delaney made 76 stock trades totaling more than $160 thousand. The largest trades involved stocks like A.O. Smith and Corpay. Their most notable trades made recently include key transactions: 
<ul>
<li>Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>): $1,001 - $15,000 Purchase</li>
<li>Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>): $1,001 - $15,000 Purchase</li>
<li>Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of April McClain Delaney's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-Techne</td>
<td>TECH</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-29</td>
</tr>
<tr>
<td>Toro</td>
<td>TTC</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-04-29</td>
</tr>
<tr>
<td>Dayforce</td>
<td>DAY</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-04-28</td>
</tr>
<tr>
<td>Markel Group</td>
<td>MKL</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-24</td>
</tr>
<tr>
<td>A.O. Smith</td>
<td>AOS</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-16</td>
</tr>
</tbody>
</table>
To keep an eye on April McClain Delaney's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/april-mcclain-delaney">real-time tracking tool</a>!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

This House of Representative Just Bought Up To $195K In Bio-Techne Stock

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues
Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope&#x2122; technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes — offering a truly integrated spatial multiomic view.
"This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue," said Dr. Matt McManus, President of Bio-Techne's Diagnostics &amp; Spatial Biology Segment. "It's a powerful step forward in understanding the dynamic interplay within tissues that drives biology and disease."

Biotech

Bio-Techne Releases Early Access Program For Next-Generation Spatial Protein Proximity Detection

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $78.83, a high estimate of $90.00, and a low estimate of $68.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $83.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207215_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Daniel Markowitz &#x7C;Evercore ISI Group &#x7C;Announces &#x7C;Outperform &#x7C; $75.00&#x7C;- &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $70.00&#x7C;$80.00 &#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $68.00&#x7C;$88.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $80.00&#x7C;$79.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $90.00&#x7C;$88.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $90.00&#x7C;$80.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bio-Techne. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bio-Techne's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bio-Techne's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TECH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bio-Techne analyst ratings.</a>
<h2>Discovering Bio-Techne: A Closer Look</h2>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Bio-Techne: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bio-Techne showcased positive performance, achieving a revenue growth rate of 8.96% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bio-Techne's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bio-Techne's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.29%, the company showcases effective utilization of assets.
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Bio-Techne

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc analyst Paul Knight downgraded the rating for Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Overweight to Sector Weight. Bio-Techne shares closed at $48.81 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor downgraded Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Neutral. Rallybio shares closed at $0.25 on Tuesday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Elizabeth Anderson downgraded the rating for Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) from Outperform to In-Line and lowered the price target from $6 to $4. Health Catalyst shares closed at $3.82 on Tuesday. <a href="https://www.benzinga.com/quote/HCAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz downgraded Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) from Buy to Hold and cut the price target from $20 to $14. Host Hotels &amp; Resorts shares closed at $12.70 on Tuesday. <a href="https://www.benzinga.com/quote/HST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev downgraded the rating for PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) from Overweight to Neutral and lowered the price target from $210 to $160. PTC shares closed at $136.74 on Tuesday.  <a href="https://www.benzinga.com/quote/PTC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-1024x601.png" alt="" class="wp-image-863721" style="width:537px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

HCAT

RLYB

This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Keybanc analyst Paul Knight downgrades Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Overweight to Sector Weight.

Keybanc Downgrades Bio-Techne to Sector Weight

The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research.

Health Care

Bio-Techne Announced An Expansion Of The Longstanding Partnership Between Its Spatial Biology Brand, Advanced Cell Diagnostics And Leica Biosystems

Bio-techne Announced It Will Open A New Customer Experience Centre In Düsseldorf, Germany To Serve Customers Across The Europe, Middle East And Africa Region And Support The Company's Long-term Regional Growth Strategy

In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bio-Techne, revealing an average target of $78.83, a high estimate of $90.00, and a low estimate of $68.00. A decline of 5.02% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1742306448_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Bio-Techne among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Techne. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bio-Techne's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Techne's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TECH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bio-Techne analyst ratings.</a>
<h2>All You Need to Know About Bio-Techne</h2>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Key Indicators: Bio-Techne's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bio-Techne's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.96% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bio-Techne's net margin is impressive, surpassing industry averages. With a net margin of 11.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.65%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bio-Techne's ROA stands out, surpassing industry averages. With an impressive ROA of 1.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Bio-Techne: What You Need To Know

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Outperform rating and announces Price Target of $75.

Initiation

Evercore ISI Group Initiates Coverage On Bio-Techne with Outperform Rating, Announces Price Target of $75

Press Releases

Bio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results

OmniAb Announces Two New Appointments to its Board of Directors

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy

ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.

Dividends

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

CAPR

OABI

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bio-Techne

空売り

Bio-Techne (NASDAQ:TECH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル